Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation.
Although the focus in treating lipid disorders is on reducing LDL cholesterol levels, triglycerides, HDL cholesterol, and Lp(a) are all independent risk factors that can be used clinically to assess cardiovascular risk. Decisions to initiate drug therapy for LDL cholesterol reduction may be influenced by levels of these other lipoprotein fractions. Data supporting intervention to modify these factors is less abundant than for LDL cholesterol reduction, but in certain circumstances drug therapy targeted at triglycerides or HDL cholesterol may be appropriate. Patients with nephrotic syndrome and end-stage renal disease are at particularly high risk for the development of cardiovascular disease and should be treated aggressively for lipid disorders. Finally, solid organ transplant recipients are almost always hyperlipidemic, and appropriate therapy could reduce cardiovascular events.
Rader
D J
DJ
Department of Medicine, University of Pennsylvania Health System, Philadelphia, USA.
Rosas
S
S
D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood*; D003131:Combined Modality Therapy; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000628:therapy*; D017270:Lipoprotein(a) / Q000097:blood*; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology / Q000628:therapy*; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology / Q000628:therapy; D012307:Risk Factors; D013959:Thyroid Diseases / Q000097:blood / Q000150:complications / Q000628:therapy*
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a)